Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide with Etoposide and Methylprednisolone in HLH
NCT05137522Unknown
- Sponsor
- Beijing Friendship Hospital
- Start
- Jul 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of tucidinostat in hemophagocytic lymphohistiocytosis (HLH), sponsored by Beijing Friendship Hospital. Primary endpoint: Evaluation of treatment response at 4 weeks. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
hemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT05137522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05137522.